Qiu Fangfang, Song Bingxin, Chen Lina, Hong Jiayi
Department of Critical Care Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Department of Respiratory and Critical Care Medicine, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Front Cardiovasc Med. 2025 May 22;12:1578970. doi: 10.3389/fcvm.2025.1578970. eCollection 2025.
Acute massive pulmonary embolism (PE) secondary to cardiac arrest (CA) is associated with extremely high mortality. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) serves as a critical life support modality; however, the safety and necessity of combined thrombolytic therapy remain controversial. This study reports the clinical outcomes of two CA patients with acute PE treated with VA-ECMO: Case 1 underwent ECMO support without thrombolysis, receiving only heparin anticoagulation. Dynamic imaging evaluation demonstrated gradual thrombus resolution, leading to successful weaning from ECMO and subsequent recovery. Case 2 received immediate thrombolysis with alteplase 50 mg after ECMO cannulation but succumbed to severe bleeding complications-including cannulation site hemorrhage, disseminated intravascular coagulation (DIC), and hemorrhagic shock-within 24 h. For ECMO-treated PE patients with CA, clinical decisions should be based on etiological assessment, bleeding risk, and multimodal evaluations (e.g., imaging, coagulation function), prioritizing individualized reperfusion strategies (such as catheter-directed thrombectomy or surgical embolectomy) to improve prognosis. Although both cases described herein received VA-ECMO as salvage therapy, their divergent thrombolytic strategies resulted in contrasting clinical outcomes, prompting critical clinical reflections on risk-benefit balancing in this high-risk population.
心脏骤停(CA)继发的急性大面积肺栓塞(PE)与极高的死亡率相关。静脉-动脉体外膜肺氧合(VA-ECMO)是一种关键的生命支持方式;然而,联合溶栓治疗的安全性和必要性仍存在争议。本研究报告了两名接受VA-ECMO治疗的CA合并急性PE患者的临床结局:病例1在未进行溶栓的情况下接受了ECMO支持,仅接受肝素抗凝治疗。动态影像学评估显示血栓逐渐溶解,最终成功撤机并随后康复。病例2在ECMO插管后立即接受了50 mg阿替普酶溶栓治疗,但在24小时内死于严重出血并发症,包括插管部位出血、弥散性血管内凝血(DIC)和失血性休克。对于接受ECMO治疗的CA合并PE患者,临床决策应基于病因评估、出血风险和多模式评估(如影像学、凝血功能),优先考虑个体化再灌注策略(如导管定向血栓切除术或外科取栓术)以改善预后。尽管本文所述的两个病例均接受VA-ECMO作为挽救治疗,但其不同的溶栓策略导致了截然不同的临床结局,促使对这一高危人群的风险-效益平衡进行重要的临床反思。